Page 2 - Specialty Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

/PRNewswire/ -- Lakewood-Amedex Inc., a privately held, clinical stage pharmaceutical discovery and development company advancing a broad portfolio of...

/PRNewswire/ -- Lakewood-Amedex Inc., a privately held, clinical stage pharmaceutical discovery and development company advancing a broad portfolio of...

Investegate announcements from NuCana plc, NuCana Appoints Elliott M. Levy, M.D. to its Board of Directors

Published: May 21, 2021 By Alex Keown Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers.  AavantiBio – Jessie Hanrahan was named chief regulatory officer of AavantiBio. Hanrahan will oversee global regulatory affairs for AavantiBio’s diversified pipeline of gene therapy programs targeting rare diseases with significant unmet medical needs. Most recently, she was Vice President of Regulatory Science at bluebird bio, Inc. Prior to bluebird bio, Hanrahan held positions of increasing responsibility at Genzyme Corp. where she...

Share this article Share this article CAMBRIDGE, Mass., May 20, 2021 /PRNewswire/ -- Omega Therapeutics, Inc. ("Omega"), a development-stage biotechnology company leveraging its OMEGA Epigenomic Programming™ platform to harness the power of epigenetics and pioneer novel DNA-sequence-based targets and develop a new class of mRNA-encoded programmable epigenetic medicines, today announced the appointment of Elliott M. Levy, M.D., to its Board of Directors. Dr. Levy is an industry veteran with over 20 years of research and development experience at global pharmaceutical companies, including Amg...